Online inquiry

IVTScrip™ mRNA-Anti-CD276, ABBV-155(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ837MR)

This product GTTS-WQ837MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & 5-Methoxy-UTP. It ecodes the monoclonal antibody that targets CD276 gene. The antibody can be applied in Solid tumors research.
Specifications
Product type mRNA
Modified bases 5-Methoxy-UTP
5' Cap Cap 0
Species Chimeric; Humanized
RefSeq NM_001024736.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 80381
UniProt ID Q5ZPR3
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CD276, ABBV-155(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) (GTTS-WQ837MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ12324MR IVTScrip™ mRNA-Anti-TIGIT, MTIG-7192-A(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA MTIG-7192-A
GTTS-WQ9934MR IVTScrip™ mRNA-Anti-EPHA3, KB-004(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA KB-004
GTTS-WQ6451MR IVTScrip™ mRNA-Anti-HA, CT-P23(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA CT-P23
GTTS-WQ2423MR IVTScrip™ mRNA-Anti-PCSK9, AMG 145(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA AMG 145
GTTS-WQ12430MR IVTScrip™ mRNA-Anti-IFNG, NI-0501(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA NI-0501
GTTS-WQ13782MR IVTScrip™ mRNA-Anti-MSTN, REGN-1033(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA REGN-1033
GTTS-WQ1849MR IVTScrip™ mRNA-Anti-IL17A, AG1-25(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA AG1-25
GTTS-WQ467MR IVTScrip™ mRNA-Anti-SELP, 42-89-glycoprotein(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA 42-89-glycoprotein
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW